subscribeSubscribe
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide

Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide
GLOBENEWSWIRE
22 Feb 2024
Share Share
Rhythm Pharma Announces Positive Reimbursement Decision in Italy for IMCIVREE

Rhythm Pharma Announces Positive Reimbursement Decision in Italy for IMCIVREE
GLOBENEWSWIRE
07 Feb 2024
Share Share
Rhythm Announces Completion of Screening for Enrollment in Setmelanotide Trial

Rhythm Announces Completion of Screening for Enrollment in Setmelanotide Trial
GLOBENEWSWIRE
04 Jan 2024
Share Share
Rhythm Receives Positive CADTH Reimbursement Recommendation for IMCIVREE

Rhythm Receives Positive CADTH Reimbursement Recommendation for IMCIVREE
GLOBENEWSWIRE
02 Nov 2023
Share Share
Rhythm Presents Data from its Long-term Extension Study of Setmelanotide

Rhythm Presents Data from its Long-term Extension Study of Setmelanotide
GLOBENEWSWIRE
17 Oct 2023
Share Share
Rhythm Receives Orphan Drug Designation from EMA for Setmelanotide

Rhythm Receives Orphan Drug Designation from EMA for Setmelanotide
GLOBENEWSWIRE
19 Sep 2023
Share Share
Rhythm Announces Pre-Marketing Early Access Authorization for Setmelanotide

Rhythm Announces Pre-Marketing Early Access Authorization for Setmelanotide
GLOBENEWSWIRE
07 Aug 2023
Share Share
Imcivree causes weight loss in patients with hypothalamic obesity

Imcivree causes weight loss in patients with hypothalamic obesity
Phalguni Deswal CLINICAL TRIALS ARENA
19 Jun 2023
Share Share
Rhythm and Genpharm Announce Collaboration to Provide IMCIVREE

Rhythm and Genpharm Announce Collaboration to Provide IMCIVREE
GLOBENEWSWIRE
22 May 2023
Share Share
Rhythm Pharma Announces Health Canada Approval of IMCIVREE® Setmelanotide

Rhythm Pharma Announces Health Canada Approval of IMCIVREE® Setmelanotide
GLOBENEWSWIRE
08 May 2023
Share Share